Alexion Pharmaceuticals, Inc.

Cornell University

Inozyme Pharma, Inc.

The Scripps Research Institute

International Aids Vaccine Initiative

Westfaelische Wilhelms-universitaet Muenster

Andre Marozsan

John S Moore

Kim Lynette Askew

Albert Cupo

Denise Devore

Susan Liu-Chen

C Richter King

Ian A Wilson

Andrew B Ward

Yan Yan

Simon Hoffenberg

Susan Faas Mcknight

Tayeba Khan

Rogier W Sanders

Michael P Caulfield

Anjli Kukreja

Julian Chandler

Jeffrey William Hunter

Rogier Sanders

Keith Bouchard

Patricia Bento

Anumeha Shah

Jean-Philippe Julien

P J Klasse

Hansi Dean

Frank Rutsch

Yvonne Nitschke

Herman Griffin

Ashmita Saigal

Per Johan Klasse

Michael Caulfield

Jean-Phillippe Julien

John Moore

Provided herein are antibodies that bind to activin receptor-like kinase 2 (ALK2) and are useful for treating bone disorders, such as those involving reduced bone mineral density and bone mineralization defects, and promoting bone growth. Also provided are polynucleotides encoding the antibodies, vectors comprising the polynucleotides, and cells that produce the antibodies.

Anti-ALK2 antibodies and uses thereof

The present invention provides methods for improving cardiovascular function in a human patient (e.g., reducing hypertension), as well as methods of treating a cardiovascular disease, by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.

Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)

The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.

Methods of treating myointimal proliferation

The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.

Treating seizure with recombinant alkaline phosphatase

The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.

Treating muscle weakness with alkaline phosphatases

Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.

Materials and methods for producing cleaved, HIV-1 envelope glycoprotein trimers

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

HIV-1 envelope glycoprotein

Growing community of inventors

Milford, CT, United States of America

Andre Marozsan